Padeliporfin is
indicated as monotherapy for adults with previously untreated, unilateral, low risk,
adenocarcinoma of the
prostate with a life expectancy of at least ten years and clinical stage
T1c or
T2a;
Gleason score ≤ 6, based on high-resolution biopsy strategies;
prostate-specific antigen (PSA) ≤ 10ng/mL; three positive cancer cores with a maximum cancer core length of 5mm in any one core or 1-2 positive cancer cores with ≥ 50% cancer involvement in any one core or a PSA density ≥ 0.15ng/mL/cm3. == Society and culture ==